For the last several quarters, Gilead Sciences’ earnings calls have been colored by anticipation for the launch of the California drugmaker's long-acting HIV pre-exposure prophylaxis (PrEP) option. | ...

Explore Gilead Sciences' Q3 2025 earnings: strong HIV portfolio growth, Yeztugo's rapid launch, and raised guidance.

Gilead has chosen a partner for lenacapavir in the race to develop new low-frequency treatments for HIV. | Gilead has chosen ...

Renata Brito, Bram Janssen, Nqobile Ntshangase and Panagiotis Mouzakis delivered an innovative presentation of powerful ...

The drug can be produced for as little as $25 per person annually, but even at $2000 per person, it can reduce new US infections almost entirely, a researcher says.

The Center for Human Rights and Public Health is sponsoring a lecture series for the following course: Current Topics in Human Rights - 340.874.01 (1st Term | 1 Credit).

In the wake of massive U.S. cuts to foreign aid, the tiny country of Lesotho in southern Africa faces deep uncertainty and worry over its HIV-positive residents.

In the wake of massive U.S. cuts to foreign aid, the tiny country of Lesotho in southern Africa faces deep uncertainty and worry over its HIV-positive residents.

India stands at the threshold of a historic opportunity – to support global efforts to end AIDS as a public health threat by 2032. Last year, two pivotal phase-3 clinical trials revealed remarkable ...

Senior officers, summoned from around the world, are entrusted to manage complex military operations. They got a lecture on fitness and grooming standards. By Greg Jaffe Reporting from Washington ...

For over three decades, HIV has played an elaborate game of hide-and-seek with researchers, making treating—and possibly even curing—the disease a seemingly insurmountable obstacle to achieve. But ...